Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms : from Bench to Bedside
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added to chemotherapy. The purpose of this review is to highlight the current evidence for CDK4/6 inhibitors in neuroendocrine neoplasms (NENs).
RECENT FINDINGS: Preclinical results showed a promising antitumor activity of CDK4/6 inhibitors in neuroendocrine tumors (NETs), but so far, the very few small clinical trials did not show a strong impact on progression free survival (PFS) and objective response in NETs. Meanwhile, the CDK4/6 inhibitor trilaciclib revealed significant effects in reducing chemotherapy-induced myelosuppression in small cell lung cancer (SCLC). Up to date, CDK4/6 inhibitors are still considered investigational in NETs as antitumor agents, whereas trilaciclib can be used in the routine clinical practice in extensive stage SCLC patients for reducing myelotoxicity of standard chemotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current oncology reports - 24(2022), 6 vom: 09. Juni, Seite 715-722 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Sousa, Maria João [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.05.2022 Date Revised 23.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11912-022-01251-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337937737 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337937737 | ||
| 003 | DE-627 | ||
| 005 | 20231225235540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-022-01251-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337937737 | ||
| 035 | |a (NLM)35262877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Sousa, Maria João |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms |b from Bench to Bedside |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2022 | ||
| 500 | |a Date Revised 23.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added to chemotherapy. The purpose of this review is to highlight the current evidence for CDK4/6 inhibitors in neuroendocrine neoplasms (NENs) | ||
| 520 | |a RECENT FINDINGS: Preclinical results showed a promising antitumor activity of CDK4/6 inhibitors in neuroendocrine tumors (NETs), but so far, the very few small clinical trials did not show a strong impact on progression free survival (PFS) and objective response in NETs. Meanwhile, the CDK4/6 inhibitor trilaciclib revealed significant effects in reducing chemotherapy-induced myelosuppression in small cell lung cancer (SCLC). Up to date, CDK4/6 inhibitors are still considered investigational in NETs as antitumor agents, whereas trilaciclib can be used in the routine clinical practice in extensive stage SCLC patients for reducing myelotoxicity of standard chemotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Abemaciclib; trilaciclib | |
| 650 | 4 | |a Neuroendocrine tumors; CDK4/6 inhibitors | |
| 650 | 4 | |a Palbociclib | |
| 650 | 4 | |a Ribociclib | |
| 650 | 7 | |a Aminopyridines |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase 6 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.22 |2 NLM | |
| 700 | 1 | |a Gervaso, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Meneses-Medina, Monica Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Spada, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Rahman, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Fazio, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 24(2022), 6 vom: 09. Juni, Seite 715-722 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:6 |g day:09 |g month:06 |g pages:715-722 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-022-01251-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 6 |b 09 |c 06 |h 715-722 | ||